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Purpose: Safety data on commonly used herbal medicinal (HM) products (HMPs) and mar-
keted in Ghana are scarce. We assessed the sub-chronic toxicity of three most-patronised
commercial antimalarial HMPs in Kumasi, Ghana.
Method: Top three HMPs (designated as herbal products ‘A’ (HPA), ‘B’ (HPB) and ‘C’ (HPC))
were selected after a mini-survey and sub-chronic toxicity evaluation conducted in accor-
dance with Organisation for Economic Co-operation and Development (OECD) 407 guide-
lines. Control rats received clean water while test groups received daily adult human dose
(DAHD), 5× DAHD or 10× DAHD of either HPA, HPB or HPC for 30 days. Rats were killed on
day 31 to obtain biochemical, haematology and histology samples for analysis. Data were
analysed by one-way analysis of variance (ANOVA) and post hoc Tukey’s test.
Results: The three HMPs produced alterations in liver morphology predominantly charac-
terised by prominent foci of fatty change with scattered hepatocytes containing intracyto-
plasmic fat globules and congested central veins and sinusoids. The lungs showed alveolar
with evidence of inflammation and foci of epithelial sloughing. Alveolar spaces were also
obscured by debris and inflammatory cells. HPA and HPC produced scattered intensely
congested heart vessels while HPB(10) produced haemorrhage and amorphous exudates
within the heart. All HMPs produced neither treatment-related deaths nor significant change
in haematological and biochemical parameters, except for HPA and HPB which decreased
(P<0.05) aspartate aminotransferase (AST) and HPB, which elevated (P<0.05) fasting blood
glucose (FBG).
Conclusion: Data from the present study suggest the potential of the herbal products (HPs),
HPA, HPB and HPC, to cause major organ-system dysfunction or damage. We advise cau-
tious use of these products and recommend further safety evaluation in chronic toxicity
models.
Introduction
Malaria is endemic in Ghana and other Sub-Saharan African countries. It is a leading cause of
morbidity and mortality among children under 5 years and pregnant women in the region [1].
In 2016, the African World Health Organization (WHO) region reported 194.4 million malaria
cases (90% of the global sum) and 405000 malaria deaths (91% of the global sum) [2,3]. Due
to the high incidence density of approximately five malaria infections per person per year for
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Sub-Saharan African [4], and the high malaria morbidity and mortality rate, antimalarial medications are of great
public interest in the region. Because of high cost and poor access toArtemisinin-basedCombination Therapy (ACT),
the use of plant-based multiherbal preparations (MHPs) for treatment of malaria is common practice in the region
[1,5]. Year-round availability, affordability and easy accessibility of plant-basedmedicines comparedwith pharmaceu-
ticalmedicines encourage their use. In fact, over 70%of Sub-SaharanAfricans resort to the use of herbalmedicines for
their primary health needs [6,7]. In our recent survey, we observed that most of the subjects used herbal medicines
solely or in combination with orthodox drug for various health needs including preventive, curative and chronic
disease management. The study participants demonstrated high level of trust in herbal medicines and believed that
herbal medicines are better curative agents than pharmaceutical medicine [8].
Most herbal medicinal (HM) products (HMPs) have been reported to be effective in treating liver problems [9],
circulatory and respiratory diseases [10], and malaria [11]. In addition, medicinal plants also offer an unlimited and
valuable recipe for the discovery of novel drugs. The lead compounds of several well-known pharmaceutical drugs
have been discovered from plants. Artemisinin used in treating Plasmodium falciparum malaria was derived from
Artemisia annua. Thememory enhancer drug, physostigmine, was first isolated from Physostigma venenosum that
grows in West Africa. Similarly, the anticancer drug, docetaxel, was originally obtained from Taxus species.
Recent scientific reports show that many medicinal plants employed as alternative medicines have adverse toxic
effects comparable with those of pharmaceutical drugs [12]. There have also been reports on potential mutagenic,
carcinogenic [13] and hepatotoxic [14] effects of some previously studied medicinal plants. Although, the leaves of
Cleistanthus collinus are believed to possess anticancer properties, they have also been shown to contain a known
human poison capable of causing mortality rate of 20–60% [15,16]. There is also a growing concern regarding con-
tamination and adulteration of over-the-counter HMPs [17]. Although, toxicity profile of some medicinal plants or
their extracts have been documented in Ghana, data on pre-market and post-market safety and toxicity are practically
unavailable for most antimalarial and other MHPs on the Ghanaian market [18]. Regular safety surveillance of these
commercial products is also lacking thereby creating data gap and raising public health concerns [19]. In our previ-
ous studies, we identified commercially available multiherbal products from the Ghanaian market with high levels
of heavy metals and banned pesticide [20,21]. Supplementary Table S1 provides a summary of the ethnomedicinal
uses and adverse or toxic effects of some medicinal plants employed in Traditional African Medicine. In the present
study, we conducted a sub-chronic toxicity evaluation for three of the multiherbal antimalarial products previously
analysed for their residual pesticide and heavy metal contents.
Materials and methods
Mini-survey and selection of herbal antimalarial products
In Ghana, consumers of HMPs do not need a doctor’s prescription to buy herbal medicine. The herbal medicine con-
sumers (both patients and healthy individuals) buy their herbal products (HPs) from several sources including herbal
centers, pharmacy shops and from thosewho sell at the roadsides,market places and to travellers in buses or at bus sta-
tions. In our previous study, amini-survey was conducted to determine themost patronised antimalarial, antidiabetic
and antihypertensive HPs on the Kumasi market [20,]. From the survey the top-three most patronised multiherbal
antimalarial products, ‘Time Herbal Mixture®’, ‘Taabea Herbal Hixture®’ and Adutwumwaa Malamix® were then
selected for further study (Supplementary Figure S1) [20,].
Study design
The study design and different stages of the study are presented in Supplementary Figure S2. Stages of the study
included HP selection, randomisation, grouping of the rats and the various studies performed on the rats.
Animals and treatment schedule
Forty young healthy adult male Sprague–Dawley rats (10–12 weeks old) were used for the study. The animals were
marked to permit easy identification and data handling and randomly assigned to ten groups of four rats per group
(n=4). Each group was assigned to a cage and all the rats were kept for 10 days to allow acclimatisation to the labora-
tory conditions prior to dosing. Animalsweremaintained at ambient temperature and humiditywith a 12-h light/12-h
dark schedule and fed with standard pelleted rodent feeds and water ad libitum during the acclimatisation and ex-
perimental periods. Each of the nine groups of rats was assigned to one herbal antimalarial dose level and the tenth
group that received clean water served as control. The animals were weighed every week prior to dosing with HPs
and before they were killed under light chloroform anaesthesia on day 30.
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The three commercial herbal products (HPs) selected for the study were assigned codes ‘HPA’, ‘HPB’ and ‘HPC’.
The equivalent of the recommended daily adult human dose (DAHD) as stated on the product labels [marked as
HPA(1), HPB(1) andHPC(1)] was used as theminimumdose and administered to rats. Five and ten times theDAHD
were regarded as middle and highest doses respectively, and were marked as HPA(5), HPB(5), HPC(5) and HPA(10),
HPB(10) and HPC(10), respectively (Supplementary Figure S1, Supplementary Tables S2 and S3). HPs and sterile
water were administered daily for 30 days via the oral route. Housing, feeding, dosing of animals and daily observa-
tions were carried out as described in the Organisation for Economic Co-operation and Development’s (OECD 407)
guideline. The number of animals assigned per group was in line with the 3R principle (reduce, refine and replace the
use of animals). Care was also taken to avoid inflicting suffering and pain on the test animals in line with international
principles and standards. The Animal Research: Reporting of In Vivo Experiments (ARRIVE) guidelines as well as
the declaration of Helsinki (revised in 2013) were also observed.
General observations
Once everyday after dosing and during the entire study period, the rats were observed for signs of toxic effects of the
test products. The observations include rats’ feeding, fur colour, self-isolation, signs of pains and death.
Assessment of haematological parameters
Blood samples for haematology were collected into tubes containing sodium ethylenediaminetetraacetic acid (EDTA)
(1% sodiumEDTA in distilledwater). Red blood cell (RBC), white blood cell (WBC), granulocyte (GRA), lymphocyte
(LYM) count, haemoglobin (HGB), haematocrit (HCT), mean corpuscular haemoglobin (MCH), mean corpuscular
volume (MCV),MCHconcentration (MCHC), platelet (PLT) count, platelet distributionwidth (PDW),mean platelet
volume (MPV) and platelet larger cell ratio (P-LCR) were estimated using haem automated analyzer (Cell Dyne:
Model 331430, Abbott Laboratories, IL, U.S.A.).
Biochemical analysis
Rats were weighed 12 h prior to euthanasia with chloroform and blood samples were collected via cardiac puncture.
Five millilitres of blood was collected into gel separator sample tubes, allowed to clot and centrifuged at 3000 rpm
for 15 min. The serum samples were separated, stored at −20◦C and used for determination of biochemical param-
eters using automated biochemistry analyser (ATAC 8000, Elan Diagnostics, CA, U.S.A.). Biochemical parameters
determined were bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase
(ALP), total protein (TP), albumin (ALB), globulin (GLO), blood urea nitrogen (BUN), creatinine (CREA), glucose
(GLU), low-density lipoprotein cholesterol (LDL-C), very LDL-C (VLDL-C), high-density lipoprotein cholesterol
(HDL-C), triglyceride (TG) and total cholesterol (CHOL).
Sperm count and fertility analysis
The analysis was carried out following standard procedures as described by Sreedhar and colleagues [22]. Briefly,
small portion of cauda epididymis was cut and crushed in 1 ml of 37◦C neutral buffer solution of sodium carbonate
(NaHCO3) to make a homogeneous mixture. Then, 2–3 drops of Nigrosine stain were added into the mixture and 10
μl of the homogenate sample was pipetted on a pre-warmed slide. Aminimum of ten fields were observed to evaluate
the sperm count under the high-power light microscope at 40× magnification.
Histology
Major vital organs (liver, heart, kidney, spleen, lungs and testis) were isolated, weighed and fixed in 10% v/v neu-
tral buffered formalin and processed for histology. Briefly, small portions of each of the organs was carefully ex-
cised, dehydrated in graded alcohol and embedded in paraffin. Sections (4–10 μm thick) were prepared, stained with
Haematoxylin and Eosin and mounted with neutral DPX medium. Examination of the slides was done using a light
microscope (×40, ×100 and ×400).
Data analysis
Results were analysed using one-tail analysis of variance (ANOVA) at 95% confidence interval. Tukey’s post hoc test
was carried out on the data using SPSS version 21. GraphPad Prism version 8.0 was used for the graphical analysis
and data were presented in charts and tables.
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Figure 1. Weekly changes in body weight
Values are expressed as mean +− SEM.
Results
Macroscopic assessment
Regular assessment of general drinking, feeding, appearance and exploratory behaviours (rearing and grooming)
during toxicological investigations are important to detect toxicity-related behavioural changes thatmay be associated
with the studied bioactive substance(s).
In the present study, general observation from macroscopic assessment of rats during the study did not show any
adverse treatment-related changes in their feeding, exploratory behaviours and drinking habits. Incisor heights, fur
colour and appearance were also normal.
Body weight
Administration of certain xenobiotic substances may interfere with the normal feeding and drinking, disruption of
gastrointestinal system and hormonal or enzymatic system interference. Feeding deterrents tend to decrease food
intake and may lead to growth retardation or loss in body weight. In the present study we monitored the weights of
the rats to assess the effect of the HPs on feeding and normal growth.
Generally, we observed weekly increases in weights across the groups for the first 3 weeks (Figure 1). Weight loss
was observed across most of the groups in the fourth week except for the control and the first dose levels of both HPB
and HPC. Continual weight loss was also observed in the highest dose group of HPB throughout the study. There
were no statistical differences between the control and the compared groups.
Parameters of haematological function
Therapeutic substances may produce adverse effects that may interfere with immunological process, inhibiting the
action of important hormones, enzymes and bymeans of interfering with normal haematopoiesis [23]. Bioactive sub-
stances may inversely influence haematopoiesis resulting in different forms of anaemia. The body also increases pro-
duction of different forms of WBCs in response to xenobiotics as part of normal body’s defense mechanism [24,25].
Haematological parameters were, therefore, assessed in the present study to determine the possible toxic effects of
the herbal preparations on haematological function.
An increase inWBC count from 9.67 +− 2.50 HPA(5) to 10.67 +− 1.24 HPA(10) was observed (Table 1). Substantial
increase inmixed cell count (MXD) consisting ofmonocytes, eosinophils, basophils (%)was also observed from13.83
+− 3.19 HPA(5) to 20.10 +− 6.93 HPA(10) and 11.83 +− 3.08 of HPB(5) to 17.13 +− 2.77 of HPB(10) (Table 2). WBC
increased from 8.57 +− 1.85 in HPB(1) to 15.07 +− 2.67 in HPB(5). Substantial MXD (%) increase was also observed
from 13.83+− 3.19HPA(5) to 20.10+− 6.93 in the highest dosed ofHPA (4699.80mg/kg bodyweight). These increases,
however, were statistically not significant when compared with the control group. The HPC did not have significant
impact on the haematological parameters when compared with the control group (Table 3).
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Table 1 Effect of HPA on haematological parameters
Parameter Control HPA(1) HPA(5) HPA(10)
WBC (×103/μl) 9.74 +− 0.52 8.13 +− 1.31 9.67 +− 2.50 10.67 +− 1.24
RBC (×106/μl) 7.81 +− 0.23 8.07 +− 0.40 7.42 +− 0.43 7.90 +− 0.67
HGB (g/dl) 14.08 +− 0.42 14.3 +− 0.67 12.67 +− 0.60 13.97 +− 0.57
HCT (%) 47.40 +− 1.34 47.63 +−2.06 41.83 +− 2.66 47.87 +− 1.94
MCV (fl) 60.72 +− 1.18 59.03 +− 0.50 56.33 +− 0.67 61 +− 2.60
MCH (pg) 18.08 +− 0.58 17.73 +− 0.12 17.10 +− 0.21 17.80 +− 0.78
MCHC (g/dl) 29.70 +− 0.45 30.00 +− 0.31 30.37 +− 0.46 29.20 +− 0.53
Platelets (×103/μl) 1152 +− 58.95 883.3 +− 198.00 1060 +− 86.53 987.3 +− 99.55
Lymphocytes (%) 75.96 +− 3.11 77.53 +− 3.50 57.23 +− 15.14 63.37 +− 9.59
MXD (%) 15.02 +− 1.87 13.83 +− 3.19 20.10 +− 6.93 18.47 +− 10.10
Neutrophils (%) 9.02 +− 1.45 8.63 +− 0.58 22.67 +− 8.89 18.17 +− 10.58
LYM #(×103) 7.34 +− 0.367 6.40 +− 1.33 5.37 +− 2.17 6.83 +− 1.33
MXD #(×103) 1.48 +− 0.24 1.07 +− 0.12 1.933 +− 0.89 1.73 +− 0.81
NEUT #(×103) 0.92 +− 0.16 0.67 +− 0.09 2.37 +− 1.13 2.10 +− 1.46
RDW SD (fl) 39.02 +− 0.91 37.90 +− 1.07 35.10 +− 0.71 36.77 +− 2.09
RDW CV (fl) 18.30 +− 0.44 18.23 +− 0.35 17.23 +− 0.87 16.50 +− 1.18
PDW (fl) 11.78 +− 0.17 13.43 +− 0.42 14.00 +− 2.30 11.77 +− 0.18
MPV (fl) 9.26 +− 0.11 10.07 +− 0.55 10.23 +− 0.94 9.43 +− 0.23
P-LCR (%) 20.18 +− 0.89 27.93 +− 4.33 28.40 +− 8.11 21.30 +− 1.42
Values are expressed as mean +− SEM. P-values less than 0.05 were considered statistically significant.
Table 2 Effect of HPB on haematological parameters
Parameter Control HPB(1) HPB(5) HPB(10)
WBC (×103/μl) 9.74 +− 0.52 8.57 +− 1.85 15.07 +− 2.67 9.13 +− 2.23
RBC (×106/μl) 7.81 +− 0.23 7.33 +− 0.48 8.28 +− 0.53 7.48 +− 0.50
HGB (g/dl) 14.08 +− 0.42 13.3 +− 0.63 14.43 +− 0.74 13.57 +− 0.85
HCT (%) 47.40 +− 1.34 44.77 +− 2.43 48.5 +− 2.96 44.43 +− 3.51
MCV (fl) 60.72 +− 1.18 61.17 +− 0.72 58.57 +− 0.27 59.3 +− 2.18
MCH (pg) 18.08 +− 0.58 18.20 +− 0.32 17.47 +− 0.42 18.17 +− 0.47
MCHC (g/dl) 29.70 +− 0.45 29.73 +− 0.23 29.80 +− 0.55 30.30 +− 0.85
Platelet (×103/μl) 1152 +− 58.95 99.55 +− 44.06 1077 +− 117.60 1266 +− 260.60
Lymphocytes (%) 75.96 +− 3.11 81.40 +− 2.23 72.03 +− 2.72 67.87 +− 4.24
MXD (%) 15.02 +− 1.87 13.03 +− 1.93 11.83 +− 3.08 17.13 +− 2.77
Neutrophils (%) 9.02 +− 1.45 5.57 +− 1.04 16.13 +− 5.72 15 +− 3.12
LYM #(×103) 7.34 +− 0.367 7.07 +− 1.68 10.73 +− 1.49 6.07 +− 1.35
MXD #(×103) 1.48 +− 0.24 1.03 +− 0.13 1.63 +− 0.18 1.57 +− 0.48
NEUT #(×103) 0.92 +− 0.16 0.47 +− 0.09 2.70 +− 1.38 1.50 +− 0.57
RDW SD (fl) 39.02 +− 0.91 37.50 +− 1.76 36.73 +− 1.28 37.60 +− 2.17
RDW CV (fl) 18.30 +− 0.44 16.33 +− 1.33 17.80 +− 1.03 17.17 +− 0.09
PDW (fl) 11.78 +− 0.17 12.40 +− 0.40 11.93 +− 0.75 13.00 +− 0.67
MPV (fl) 9.26 +− 0.11 9.80 +− 0.38 9.33 +− 0.27 10.13 +− 0.37
P-LCR (%) 20.18 +− 0.89 23.83 +− 2.83 20.57 +− 2.64 27.13 +− 2.98
Values are expressed as mean +− SEM. P-values less than 0.05 were considered statistically significant.
Parameters of biochemical function
AST is primarily found in the cytoplasm and mitochondria of cardiac muscle, liver and skeletal muscle [26]. ALT,
on the other hand, is found primarily in the cytosol of hepatic cells. During necrosis, liver injury or alteration in
hepatocellular permeability, liver enzymes leak into the bloodstream and serum levels of these enzymes, therefore,
serve as good markers for assessment of hepatotoxicity. AST and the specific liver enzyme, ALT, are used to assess
the integrity of the hepatic cells since they give indication of the degree of hepatocytes degeneration [12]. Indirect
bilirubin is formed from the breakdown of RBC’sHGB. It is conjugated to glucuronic acid in the liver (direct bilirubin)
© 2020 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
License 4.0 (CC BY).
5
D
ow
nloaded from
 https://portlandpress.com
/bioscirep/article-pdf/40/6/BSR
20192536/883408/bsr-2019-2536.pdf by H
elsinki U
niversity Library user on 03 July 2020
Bioscience Reports (2020) 40 BSR20192536
https://doi.org/10.1042/BSR20192536
Table 3 Effect of HPC on haematological parameters
Parameter Control HPC(1) HPC(5) HPC(10)
WBC (×103/μl) 9.74 +− 0.52 11.10 +− 1.04 11.77 +− 0.45 7.13 +− 2.45
RBC (×106/μl) 7.81 +− 0.23 8.01 +− 0.16 7.73 +− 0.53 8.06 +− 0.38
HGB (g/dl) 14.08 +− 0.42 14.43 +− 0.54 13.97 +− 0.56 14 +− 0.17
HCT (%) 47.40 +− 1.34 47.77 +− 1.67 45.03 +− 1.65 46.8 +− 0.60
MCV (fl) 60.72 +− 1.18 59.6 +− 1.07 58.5 +− 2.34 58.3 +− 2.91
MCH (pg) 18.08 +− 0.58 18.03 +− 0.41 18.13 +− 0.64 17.43 +− 0.73
MCHC (g/dl) 29.70 +− 0.45 30.20 +− 0.15 31.00 +− 0.17 29.93 +− 0.77
Platelet (×103/μl) 1152 +− 58.95 1135 +− 144.60 1058 +− 80.71 1020 +− 57.30
Lymphocytes (%) 75.96 +− 3.11 71.93 +− 4.04 65.80 +− 6.05 72.53 +− 9.12
MXD (%) 15.02 +− 1.87 16.80 +− 2.33 21.67 +− 3.58 11.57 +− 2.39
Neutrophils (%) 9.02 +− 1.45 11.27 +− 1.73 12.53 +− 2.48 15.90 +− 6.91
LYM #(×103) 7.34 +− 0.367 8.00 +− 0.95 7.77 +− 0.87 4.77 +− 1.09
MXD #(×103) 1.48 +− 0.24 1.83 +− 0.23 2.53 +− 0.41 0.90 +− 0.50
NEUT #(×103) 0.92 +− 0.16 1.27 +− 0.20 1.47 +− 0.29 1.47 +− 0.97
RDW SD (fl) 39.02 +− 0.91 38.50 +− 0.71 35.73 +− 1.43 35.70 +− 2.85
RDW CV (fl) 18.30 +− 0.44 18.23 +− 0.47 16.73 +− 0.73 17.00 +− 0.76
PDW (fl) 11.78 +− 0.17 12.57 +− 0.32 12.70 +− 0.66 11.67 +− 0.37
MPV (fl) 9.26 +− 0.11 9.87 +− 0.30 10 +− 0.45 9.63 +− 0.19
P-LCR (%) 20.18 +− 0.89 25.27 +− 2.04 26.40 +− 4.25 22.13 +− 2.03
Values are expressed as mean +− SEM. P-values less than 0.05 were considered statistically significant.
and excreted via bile. Bilirubin test is important to access degree of RBC haemolysis and the catabolic function of
the liver during bioactive toxicity studies. The kidney plays important role in excreting waste substances including
bilirubin and urea from the body. In addition, the liver also plays a crucial role in protein and lipid biosynthesis in the
body. Approximately 80% of cholesterol used in the mammalian body is endogenously made. Most cells of the body
synthesise cholesterol for their own usage while the liver’s cholesterol is for transportation and other purposes. Most
serum endogenous cholesterol therefore has the liver as its origin and their levels may, among other things, tell about
the synthetic ability of the liver after drug administration.
Creatinine (the waste product from the normal wear and tear on muscles of the body) and blood urea nitrogen
(byproduct of protein metabolism) are cleared regularly by the kidney [27]. The levels of serum creatinine and blood
urea nitrogen are therefore useful indicators of kidney function. We observed that indirect bilirubin levels increased
with dose for HPA but decreased with increasing doses of HPB. Albumin, total and direct bilirubin levels also de-
creased with increasing doses for HPA. A significantly lowAST activity was observed in themiddle-dose level of HPA
and at all dose levels of HPC when compared with the control group (Figure 2). The effects of HPA and HPB on AST
and ALT activities were not dose related. Albumin level was also significantly low in HPB(5) dose group (Figure 2).
The least, middle and the highest dose groups of ASTwere all significantly lowwhen comparedwith the control group
(Figure 2). LDL-C level non-significantly increased at the dose of HPB(10) while VLDL-C level substantially reduced
for HPB(10) group. Reduced HDL-C and CHOL levels were also observed for HPB(5). Fasting blood sugar levels for
HPB(1) and HPB(10) were significantly higher than in the control group (Figure 3). Most of the lipid parameters for
rats in the HPC groups were not significantly different from those of the control group (Figure 3). Similarly, serum
creatinine and blood urea nitrogen of all dose groups of HPA, HPB and HPC were not significantly different from
the control group (Figure 3).
Relative organ weight
Toxic effects exerted by certain bioactive substances are capable of inducing inflammatory responses in different
tissues and organs leading to damage. Inflammation in essential organs may lead to increase in weight and higher
organ-to-body weight ratios compared with the normal organs. Organ weights and organ-to-body weight ratio com-
parison between the treated groups and the control has conventionally been used to evaluate toxic effects of bioactive
products. The Society of Toxicologic Pathology considers organ weight evaluation to be an important screening tool
in characterising the toxicity of a bioactive substances in general toxicity studies [28]. In the present study the weights
of the heart, liver, kidney, spleen and testis and their relative weights with regards to the body weights were evaluated.
6 © 2020 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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Figure 2. Serum activities of liver enzymes and levels of proteins and bilirubin
Values are expressed as mean +− SEM. Statistical difference between the test group and the control at 95% CI is marked with * at
P-values less than 0.05. (A-C): levels of serum proteins, (D-F): serum activities of liver enzymes, (G-I): serum bilirubin concentrations.
The relative kidney weight of rats in the least dose group of HPC (774.00 mg/kg body weight) was significantly
lower than those of the control group. Similarly, the relative lung weight of rats in the highest dose group of HPB
(3999.60 mg/kg body weight) was significantly higher when compared with the control group (Figure 4). However,
© 2020 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
License 4.0 (CC BY).
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Figure 3. Lipid profile, serum creatinine, blood urea nitrogen, blood sugar and sperm count
Values are expressed as mean +− SEM. Statistical difference between the test group and the control at 95% CI is marked with *
at P-values less than 0.05. (A-E): serum lipid profile, (F): serum creatinine concentration, (G): blood urea nitrogen, (H): blood sugar
concentration, (I): sperm count.
the weights of the heart, the liver, the spleen and the testis of the test groups were not significantly different from the
control group.
8 © 2020 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
License 4.0 (CC BY).
D
ow
nloaded from
 https://portlandpress.com
/bioscirep/article-pdf/40/6/BSR
20192536/883408/bsr-2019-2536.pdf by H
elsinki U
niversity Library user on 03 July 2020
Bioscience Reports (2020) 40 BSR20192536
https://doi.org/10.1042/BSR20192536
Figure 4. Relative organ weights per 100 g body weight
Values are expressed as mean +− SEM. Statistical difference between the test group and the control at 95% CI is marked with *.
Organ to body weight ratio (g/100g body weight) of (A): kidney, (B): liver, (C): lung, (D): heart, (E): spleen, (F): testes.
Histologic assessment
Analysis of themicroscopic structure of essential tissues and organs is often recommended in toxicity or safety assess-
ment of bioactive substances [29]. Such histological evaluation is crucial in detecting presymptomatic toxic effects
that may not be observed in biochemical analysis. In the present study, we examined themicroscopic structures of the
heart, lung, liver, kidney, spleen and testis of the experimental animals after exposure to the HMPs.We also examined
these organs in the control group to allow for comparison.
© 2020 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
License 4.0 (CC BY).
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Infertility among married couples is on the increase in Ghana [30,31] and finding the cause is a concern to all
public health practitioners. Certain bioactive substances impair fertility by adversely affecting spermatogenesis. We
therefore, assessed sperm quality and quantity in the present study in order to determine the impact of the herbal
preparations on fertility of the male rats.
Liver
Liver sections of control rats revealed a moderate to severe level of congestion within the central veins (Figure 5A).
Sections from the liver of rats that received HPA(1–10) exhibited congestion within the central veins, sinusoids,
large vessels and under the capsule suggesting subcapsular haemorrhage (Figure 5B–D). In addition, foci of necrosis
without evidence of inflammation were observed in HPA(1) dose group. Also, scattered individual hepatocytes that
showed intracytoplasmic fat globules were seen in rats that received HPA(5) and HPA(10). The liver of rats given
HPB(1) exhibited central vein congestion (Figure 5E). Also, liver section from rats administered with HPB(5) and
HPB(10) showed normal architecture with congestion of central veins and sinusoids (Figure 5F,G). In addition, the
hepatocytes of rats in the HPB(5) group revealed prominent foci of fatty changes with mainly microvesicular confor-
mation. Rats in the HPC(1, 5,10) dose groups (Figure 5H–J) revealed liver sections with congestion within the central
veins, sinusoids, large vessels and under the capsule. In addition, a focus of foamy hepatocytes was observed in rats
treated with HPC(5).
Kidney
Control rats and the group that received HPB(1) showed normal renal architecture with normal glomeruli. Renal
tubules and collecting ducts showed mild congestion within their stroma (Figure 5K,O). All HPA, HPB and HPC
dose groups except HPB(1) showed renal tubules and collecting ducts with mild congestion within their stroma and
within the glomeruli (Figure 5). In addition, there were foci of chronic inflammatory change in the highest dose group
of HPC (Figure 5T).
Heart
Scattered intensely congested heart vessels, without evidence of inflammation, infarction or fibrosis were observed
at all dose levels of HPA (Figure 5V–X) and HPC(1, 5, 10)-treated groups (Figure 5Ab–Ad). Intensely eosinophilic
muscle fibres, haemorrhagewith associated amorphous exudates in isolatedmuscle fibres as well as scattered intensely
congested vessels were seen in the heart sections of rats that received HPB(10) (Figure 5Aa).
Lungs
Lung sections of rats that received clean water showed foci of epithelial sloughing within the airway (Figure 6A). Evi-
dence of chronic inflammation and groups of chronic inflammatory cells filling alveolar spaces and foci of sloughing
within the airway were observed in HPA(1)-treated rats (Figure 6B). Rats in the HPA(5) group had lungs that showed
chronic inflammatory changes dominated by lymphocytes and macrophages with sloughing of epithelial cells. The
alveolar spaces were obscured by debris and chronic inflammatory cells (Figure 6C). Lungs of rats given HPA(10)
also showed moderate chronic inflammatory changes dominated by lymphocytes and macrophages with sloughing
of epithelial cells in some areas. The alveolar spaces are obscured by debris and chronic inflammatory cells (Figure
6D). Rats that receivedHPB(1) showed lung exhibiting thickened alveolar septae and chronic inflammatory cells with
congestion within the lung parenchyma. There was also evidence of non-specific chronic inflammation (Figure 6E).
Sections of lung from rats that received HPB(5) showed alveolar with evidence of chronic inflammation in some ar-
eas with groups of chronic inflammatory cells. There were foci of sloughing within the airway (Figure 6F). The lung
section of rats treated with HPB(10) exhibited alveolar that showed little evidence of inflammation in some areas
and foci of sloughing within the airway (Figure 6G). Alveolar with evidence of moderate chronic inflammation in
many areas with groups of chronic inflammatory cells filling alveolar spaces were observed in lung section of rats
that received HPC (Figure 6H–J). In addition, there were foci of sloughing observed within the airway of HPC(1, 5,
10)-treated groups.
Spleen
The HPs (HPA, HPB and HPC) did not affect the histology of the spleens of the rats when compared with the control
group (Figure 6K–T).
10 © 2020 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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Figure 5. Photomicrographs of the liver, kidney and heart for the sub-chronic toxicity studies of Sprague–Dawley rats
treated with either sterile water, HPA, HPB or HPC for 30 days
Magnification, ×100. Haematoxylin–Eosin stain was used. Photomicrographs of sections of (A-J): liver, (K-T): kidney, (U-Z) and
(Aa-Ad): heart.
© 2020 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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Figure 6. Photomicrographs of the lung, spleen and testis for the sub-chronic toxicity studies of Sprague–Dawley rats
treated with either sterile water, HPA, HPB or HPC for 30 days
Magnification, ×100. Heamatoxylin–Eosin stain was used. Photomicrographs of sections of (A-J): lung, (K-T): spleen, (U-Z) and
(Aa-Ad): testis.
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Testis
Sections of testis from control rats and from rats that received different doses of HPA, HPB and HPC showed nor-
mal architecture with seminiferous tubules containing cells at all stages of spermatogenesis without any evidence of
inflammation or adverse drug effect (Figure 6U–Ad).
Discussion
HMPs are commonplace on the Ghanaian market and their use is on the increase due to the growing demand for
nature-based products. In spite of the huge patronage and extensive use of HMPs formanagement of various ailments
in Ghana, information regarding their safety is seldom available. The paucity of scientific data on the possible harmful
effects of these multiherbal products prompted the present investigation in which we evaluated the safety of the three
most patronised antimalarial HMPs in the Kumasi metropolis of Ghana in an experimental model of sub-chronic
toxicity study. Data from the present study did not reveal any significant impairment of haematological function or
treatment-related deaths in the various test groups. Red blood cell and WBC counts with differential analysis did
not reveal any signs of macrocytic or microcytic anaemia in all groups that received the HPs. While slight elevation
was observed in the RBC counts of some groups, the values were not significantly different from those of the control
group and as such was considered toxicologically not important. Similarly, HPB (middle and high dose levels) and
HPC (low and middle dose levels) increasedWBC counts, although values were not statistically different from those
of the control.Macroscopic examination of gastrointestinal tract after animals were killed and dissected revealedmild
ulcerations in the small intestines of rats that received HPB (high dose).
Our results also showed that sub-chronic administration of HPA (at low and middle doses) and HPC (at all doses)
significantly decrease AST in the rats. These findings suggest either a liver protective effect, chronic toxic effect or
death of the liver cells due to extensive toxic effect of the HPs. It could also be a mixture of some of these effects
since the products have been stated to comprise three to five different herbal plants with different pharmacological
properties. The argument for a possible liver protective effect by HPC is partly supported by previous studies which
found one of the active ingredient of HPC ‘Phyllanthus fraternus’ to possess antihepatotoxic activity [32,33], justi-
fying its used in traditional medicine for the treatment of jaundice. This assertion on HPC also correlates well with a
clinical trial of the same product which was published at the time this current study was ongoing [34]. On the other
hand, the argument for a possible chronic liver toxicity induced by the HPs is supported by the previously identified
chemical toxicants in these products [20,35]. Histologic findings from this study, however, support the induction of
liver toxicity by the HMPs. For instance, congestion of sinusoids, within the large vessels and under the capsule were
observed in all dose groups of HPA, HPC and HPB(5 and 10). There were foci of necrosis in HPA(1), hepatocytes
with intracytoplasmic fat globules in HPA(5 and 10), hepatocytes with prominent foci of fatty change with mainly
microvesicular conformation in HPB(5) group and congestion within the large vessels and under the capsule and a
focus of foamy hepatocytes observed in HPC(5). In addition, the fat globules observed in HPA(5 and 10) affected
the liver’s synthetic ability leading to a significantly low albumin level in HPA(5). The assertion was strengthened by
the fact that the albumin/globulin ratio of HPA (5 and 10) group was much less when compared with control group.
A component of the HPC ‘Vitex grandifolia’ had previously been identified to be toxic to Sprague–Dawley rats and
this conforms well with the toxic observations made in the present study.
The fasting blood sugar levels for rats treated with low and high doses of HPB (1 and 10) were significantly
higher when compared with the control group. This hyperglycaemia may suggest possible interference with glucose
metabolism or injury to the pancreas and a possible predisposition of the rats to diabetes mellitus. The association of
hyperglycaemia and development of diabetes mellitus has been well studied [36]. By extension, since the least dose
of HPB(1) (which is the equivalent dose recommended for human use) significantly increased blood glucose levels
in the rats, it is likely that chronic exposure at this dose may predispose the consumer to the risk of diabetes mellitus.
Furthermore, rats administered with HMPs (at all dose levels) exhibited signs of moderate lung toxicity. This is ev-
ident from lung histology that revealed signs of pulmonary toxicity characterised by inflammation in all dose groups
of HPA and HPB, in addition to congestion and presence of chronic inflammatory cells in rats that received HPC. In
addition, the relative weight of the lungs of HPB(10) group was significantly higher than that of the control group. In
our recent study, we identified HPs (A, B and C) to have been contaminated with nickel, lead and chromium (residual
contents greater than maximum residual limit (MRL) values) [29], and previous studies have also linked Ni overex-
posure to lung injury, inflammation, fibrosis and cancer of the respiratory tract [37]. Considering the dose-related
inflammatory changes in the rat lungs and other signs of pulmonary toxicity, it is possible, therefore, that exposure
to the Ni content of the HPs may contribute to the observed lung toxicity.
© 2020 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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Data from the present study further revealed that rats treated with HPB(10) also exhibited gastrointestinal lesions,
especially in the small intestine. GIT lesions are typical signs of chromium (VI) toxicity [38,39]. The induction of GIT
lesions by HPB seems to correlate with our recent study where we reported the presence of significantly high levels of
Cr aboveMRL limit in this herbal preparation [20]. Similar morphological changes were observed in the lungs of rats
that received HPC with the alveolar showing inflammatory changes dominated by lymphocytes and macrophages
and alveolar spaces obscured by debris and chronic inflammatory cells which could be attributed to the heavy metal
contaminations previously identified at concentrations above their respective MRL values [20,37].
We also observed signs of mild kidney toxicity in rats administered with HPA and HPB (at all dose levels) and
moderate kidney toxicity in rats given HPC(1–10), characterised by congestion within the glomerular capillary and
the stroma of the renal tubules and collecting ducts. Foci of chronic inflammation were also seen in rats that received
HPC(10). In addition, the relative kidney weight of the rats that received HPC(1) was significantly lower than those
of the control group. The chronic inflammation and possible occurrence of atrophy could explain the significantly
low relative kidney weight in HPC(1) [40,41]. The observed foci of chronic inflammation in the present study may
be related to the presence of heavy metals (arsenic, chromium and nickel) and pesticides (aldrin and dieldrin) as
previously stated and reported in our recent article [20]. This also correlates with previous findings on chromium
(VI), [38] arsenic [42], and aldrin [37] toxicities.
We observed that the HMPs (HPA, HPB andHPC), at the dose given and duration of administration in the present
study, did not exert any adverse influence on sperm characteristics. This is evident in the similarity between sperm
count and sperm morphology of test rats and those of the control group.
Sub-chronic administration of HPA(1-10) and HPC(1-10) to rats caused moderate myocardial toxicity marked by
scattered but intensely congested vessels. The heart sections of rats given HPB(10) show foci of intensely eosinophilic
muscle fibres, haemorrhage with associated amorphous exudates, isolated muscle fibres and scattered intensely con-
gested vessels. This effect may in part be attributable to the high concentration of heavy metals like arsenic in these
products [20]. Association of arsenic and inflammatory damage to the vascular system has been reported in litera-
ture. Inflammatory changes and vascular congestion are signs typically associated with arsenic heart toxicity [42,43].
Although the various medicinal plant components of the antimalarial HMPs investigated in this study may be linked
to the toxic effects observed in the rats, we strongly believe that the heavy metal and pesticide contaminants found in
these herbal preparations are also playing a major role.
Conclusion
Data from the present study suggest the potential of the HPs, HPA, HPB and HPC, to cause major organ-system
dysfunction or damage. The observed toxic effects of these HMPs may be related in part to their contamination with
heavy metals and pesticides. The need for alternative, safe drugs for treatment of malaria is huge. We recommend the
use of these HPs with caution and suggest further assessment of their safety in a chronic model of toxicity. We also
recommend good manufacturing as well as safe farming practices to reduce contamination of herbal medicines with
heavy metals, pesticides or other pollutants.
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